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Upon stimulation by microbial products through TLR, dendritic cells (DC) acquire the capacity to prime naive T cells and to
initiate a proinflammatory immune response. Recently, we have shown that APC within the CNS of multiple sclerosis (MS)
patients contain peptidoglycan (PGN), a major cell wall component of Gram-positive bacteria, which signals through TLR and
NOD. In this study, we report that Staphylococcus aureus PGN as a single component can support the induction of experimental
autoimmune encephalomyelitis (EAE) in mice, an animal model for MS. Mice immunized with an encephalitogenic myelin oli-
godendrocyte glycoprotein peptide in IFA did not develop EAE. In contrast, addition of PGN to the emulsion was sufficient for
priming of autoreactive Th1 cells and development of EAE. In vitro studies demonstrate that PGN stimulates DC-mediated
processes, reflected by increased Ag uptake, DC maturation, Th1 cell expansion, activation, and proinflammatory cytokine pro-
duction. These data indicate that PGN-mediated interactions result in proinflammatory stimulation of Ag-specific effector func-
tions, which are important in the development of EAE. These PGN-mediated processes may occur both within the peripheral
lymph nodes as well as in the CNS and likely involve recognition by TLR on DC. Thus, PGN may provide a physiological trigger
of DC maturation, and in this way disrupt the normal tolerance to self Ag. As such, PGN signaling pathways may serve as novel
targets for the treatment of MS. The Journal of Immunology, 2005, 174: 808–816.
M ultiple sclerosis (MS)2 is considered to be a chronicautoimmune disease of the CNS of unknown etiologycritically driven by CD4 Th1 cells. However, the
presence of autoreactive T cells is clearly not the single determin-
ing factor for the development of MS, because myelin-reactive T
cells are also found in healthy individuals (1, 2). This implies that
other factors play an important role in the initiation and perpetu-
ation of pathological autoantigen-specific immune processes.
Bacteria and viruses are prominent cofactors that have been im-
plicated in autoimmune disease initiation and persistence (3). As
such, it has been shown that MS relapses are frequently associated
with antecedent infections (4, 5), which in some cases are bacterial
(6). In experimental autoimmune encephalomyelitis (EAE), an an-
imal model for MS, a strong adjuvant containing killed whole My-
cobacterium tuberculosis (CFA) is required for disease induction.
When IFA emulsion is being used, animals will not develop EAE
(7, 8). Microbial components, such as CpG-DNA and LPS, are
physiological stimuli of EAE development via innate receptors on
APC (9–11). These data indicate that noninfectious microbial
components contribute to disease development in EAE and likely
in MS.
Peptidoglycan (PGN) is an important bacterial cell wall com-
ponent implicated in chronic inflammation (12). We have previ-
ously demonstrated that PGN isolated from sterile human spleen
stimulates T cell proliferation and cytokine production (13). Fur-
thermore, we have shown that phagocytic cells may distribute
PGN to sites of chronic inflammation. At these sites, PGN-con-
taining dendritic cells (DC) and macrophages (M) are present in
high numbers and express costimulatory molecules and cytokines,
as revealed by extensive in situ analysis of MS brain tissue (14)
and rheumatoid arthritis synovial tissue (15, 16). In conclusion,
these data support the concept that biologically active PGN can be
transported by APC to lymphoid tissues and sites of chronic in-
flammation. Therefore, we hypothesized that PGN acts as a sup-
porting factor of autoimmune processes in MS.
As a mechanism of action, PGN can activate the innate immune
system through binding of extracellular and intracellular receptors
(17–19). Extracellular PGN has been claimed to bind TLR2 in
association with CD14, expressed on the cell surface of APC.
Some internalized TLR ligands can also engage TLR in phago-
somes (20). In addition, two new intracellular receptors for PGN
fragments, NOD1/2 (CARD4/15) have been described recently
(21, 22). Although high numbers of immunocompetent PGN-con-
taining APC were found in MS brain tissue by in situ analysis, a
functional role for PGN in the pathogenesis of MS remains to be
elucidated. Therefore, we assessed the role of PGN in the devel-
opment of mouse EAE. To achieve this, mice were immunized
with autoantigen emulsified in IFA supplemented with PGN. We
used PGN derived from Staphylococcus aureus, which does not
contain the motif required for NOD1 ligation (22), but contains the
motif necessary for NOD2 ligation (23, 24). Mice were assessed
for EAE development, and draining lymph nodes were analyzed
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for the presence of PGN-containing cells. Because DC play a
prominent role in linking the innate and adaptive immune re-
sponse, we assessed the functional role of PGN in Ag uptake, DC
maturation, and T cell polarization. Taken together, our data show
that proinflammatory PGN stimulates the development of autoim-
mune-mediated processes in EAE.
Materials and Methods
Mice
Female C57BL/6 mice (8–12 wk old) and BALB/c mice (6–10 wk old)
were purchased from Harlan (Horst, The Netherlands). OVA323–339-spe-
cific, MHC class II (MHC-II)-restricted, TCR transgenic (OT-II) mice,
backcrossed on the C57BL/6 background, were bred within the facility. All
animal experiments were performed with approval of the Erasmus Univer-
sity MC committee (Rotterdam, The Netherlands) for animal ethics. Mice
were housed under specified pathogen-free conditions and received water
and food ad libitum. Paralyzed mice with EAE scores 2.5 were afforded
easier access to food and water.
Peptides, Abs, and PGN
Myelin oligodendrocyte glycoprotein (MOG)35–55 (MEVGWYRSPFSRV-
VHLYRNGK) was a kind gift from Dr. U. Gu¨nthert (Basel University,
Basel, Switzerland). Soluble PGN (sPGN) was prepared from S. aureus by
gel-permeation chromatography (25), and insoluble PGN (iPGN) was pre-
pared with standard methods. The LPS content of both PGN fractions was
rigorously checked and was 13 pg of LPS per milligram of PGN as
measured by Limulus amebocyte lysate assay, which are background val-
ues. Absence of LPS was further confirmed by in vitro culture with mouse
bone marrow-derived DC. Purification and identification of the biologically
active components in the sPGN fractions are currently being performed,
and might reveal other TLR2 agonists as recently described by Travassos
et al. (26).
PGN of all bacterial species is composed of two alternating sugar res-
idues, N-acetyl glucosamine and N-acetyl muramic acid, forming glycan
strands. These strands are connected via stem peptides that differ from one
bacterial species to another, and that have the sequence L-alanine-D-iso-
glutamine-L-lysine-D-alanine-D-alanine in S. aureus. In addition, PGN from
S. aureus contains pentaglycine bridges. The complete PGN network is a
highly complex ordered network, the detailed structure of which is a sub-
ject of debate to this day (27). The two main hydrolyzing enzymes capable
of PGN degradation are lysozyme and N-acetylmuramyl-L-alanine amidase
(NAMLAA), which is identical with PGN recognition protein-L (PGRP-L)
(28, 29). Lysozyme hydrolyzes the bond between the two sugar moieties,
whereas NAMLAA/PGRP-L hydrolyzes the lactate bond between N-acetyl
muramic acid and the amino group of the first L-alanine.
Induction and clinical evaluation of EAE
C57BL/6 mice were immunized s.c., at four sites (axillar and inguinal),
with 200 g of MOG35–55 in 0.1 ml of PBS emulsified in an equal volume
of CFA containing 200 g of M. tuberculosis (H37/Ra; Difco Laborato-
ries). Additionally, mice were injected i.p. with 200 ng of Bordetella per-
tussis toxin in 0.2 ml of PBS on days 0 and 2 after immunization (Sigma-
Aldrich). Mice were weighed and scored for clinical signs of EAE daily
according to the following scoring system: 0, no disease; 0.5, partial tail
paralysis; 1, complete tail paralysis; 1.5, limb weakness without tail pa-
ralysis; 2, limb weakness and tail paralysis; 2.5, partial limb and tail pa-
ralysis; 3, complete hind or front limb paralysis; 3.5, paraplegia; 4, quad-
riplegia; 5, death due to EAE.
Histology
The immunohistochemical techniques used in this study have previously
been described in detail (30, 31). In brief, frozen sections of 6 m were
thaw-mounted on gelatin-coated glass slides and stored overnight in a hu-
midified atmosphere. Sections were air-dried for 1 h and fixed at room
temperature in fresh acetone containing 0.02% (v/v) H2O2. Then the slides
were air-dried for 10 min, washed with PBS, and incubated with prede-
termined optimal dilutions of reagents overnight at 4°C in a humidified
atmosphere. Secondary and tertiary reagents were applied and incubated
for 1 h at room temperature. Between each incubation, slides were washed
twice with PBS/0.05% Tween 20. HRP converted 3-amino-9-ethyl-carba-
zole into a bright red precipitate upon incubation for 10 min. Incubation of
slides with naphthol-AS-MX phosphate (Sigma-Aldrich) and fast blue BB
base (Sigma-Aldrich) for 30 min at 37°C resulted in a blue precipitate
indicating alkaline phosphatase activity. As a negative control, the primary
Ab was omitted. Nuclei were counterstained by hematoxylin.
Four to 7 wk after immunization, mice were euthanized using CO2, and
brain tissues were snap frozen in liquid nitrogen and stored at 80°C. To
determine the cellular infiltration in the CNS, immunohistochemical stain-
ings were performed on frozen sections with anti-mouse B220 (RA-3-6B2;
BD Pharmingen), anti-human cross-reactive to mouse CD3 (DakoCytoma-
tion), and anti-mouse MHC-II (M5/114). For CD3, donkey anti-rabbit Ig-
biotin (Amersham Biosciences) was used as a conjugate. For B220 and
MHC-II, rabbit anti-rat IgG-biotin (DakoCytomation) was used as a con-
jugate. As a tertiary step, slides were incubated with ABComplex-HRP
(DakoCytomation).
To assess the presence of PGN within the draining lymph nodes, we
isolated axillary and inguinal lymph nodes at 4 and 96 h after immuniza-
tion. Lymph nodes were snap frozen in liquid nitrogen and stored at
80°C. A double-staining procedure was used to determine which cell
types contain PGN. PGN-containing cells were detected with mAb 15704-
biotin (Gentaur Molecular Products) raised against S. aureus PGN, fol-
lowed by streptavidin-FITC (BD Biosciences). DC were detected by in-
cubation with anti-mouse CD11c-PE (HL3; BD Biosciences).
Uptake of OVA by DC
DC were prepared as previously described (32). Briefly, bone marrow was
flushed with RPMI 1640 (Invitrogen Life Technologies) from femurs and
tibiae of C57BL/6 mice. Cells were washed, enumerated, and plated in
bacteriological 100-mm diameter petri dishes. Cell culture medium (TCM)
was RPMI 1640 supplemented with gentamicin (60 g/ml; Invitrogen Life
Technologies), 2-ME (5  105 mol/L; Sigma-Aldrich) and 5% (v/v) FCS
(Biocell Laboratories). At day 0 of the culture, the cells were seeded at a
concentration of 2  106/dish in medium containing recombinant mouse
GM-CSF (200 IU/ml; kindly provided by K. Thielemans (University of
Brussels, Brussels, Belgium)). At day 3, TCM containing 200 IU/ml re-
combinant mouse GM-CSF was added. At days 6 and 8, half of the me-
dium was collected and centrifuged, and the pellet was resuspended in
TCM containing 200 IU/ml recombinant mouse GM-CSF. At day 9, 100 l
TCM containing 1  105 DC were plated in round-bottom 96-well plates
for 30 min at 4 or 37°C. DC were pulsed with different concentrations (0,
FIGURE 1. Both sPGN and iPGN are potent adjuvants for the induction
of EAE. A and B, In two separate experiments, C57BL/6 mice were im-
munized with MOG35–55 emulsified in CFA (F). In A, mice were immu-
nized with MOG35–55 in IFA (f), or IFA-25 g sPGN (E). In B, mice were
immunized with IFA-400 g iPGN (E). Mice were weighed and scored for
clinical signs of EAE daily. Five animals were used for each group. Graphs
show mean clinical scores of animals that developed EAE. d.i., Disease
incidence.
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0.01, 0.1, 1 mg/ml) of OVA-FITC (Molecular Probes). The endotoxin level
of FITC-OVA determined by a Limulus amebocyte lysate assay (BioWhit-
taker) was 0.001 g, which was previously reported not to affect DCs
(33). DC were stimulated with 10 g/ml sPGN or iPGN. Cells were stained
for 30 min at 4°C with anti-CD11c-allophycocyanin (HL3; BD Bio-
sciences) dissolved in PBS containing 0.5% BSA and 0.01% sodium azide.
Uptake of OVA-FITC was determined on CD11c-allophycocyanin-gated
cells by flow cytometry. Dead cells and debris were excluded using pro-
pidium iodide.
DC maturation assay
At day 9 of the culture, DC were pulsed overnight with either 100 ng/ml
LPS, or 10 g/ml sPGN or iPGN. To exclude LPS contamination of the
PGN preparation, polymyxin B was added to the culture. Cells were cen-
trifuged, and supernatants were collected for cytokine analysis (IL-6, IL-
10, IL-12p70, and TNF-). The maturation state of DC was determined by
staining for 30 min with mAbs anti-CD11c-allophycocyanin, anti-MHC-
II-FITC (M5/114.5.2), in combination with anti-CD40-PE (3/23), anti-
CD80-PE (16-10A1), and anti-CD86-PE (GL-1) (all obtained from BD
Biosciences) diluted in PBS containing 0.5% BSA and 0.01% sodium
azide. Maturation of DC was determined on CD11c-allophycocyanin-gated
cells by flow cytometry. Dead cells and debris were excluded using pro-
pidium iodide.
OVA-specific T cell proliferation assay
DC were obtained from bone marrow culture as described above. At day 9
of culture, DC were plated in 24-well plates containing 2 ml of TCM, and
pulsed with 10 mg/ml OVA-Worthington (Biochemical) for 24 h. At the
dose we used in our experiments, the endotoxin level of OVA measured by
a Limulus amebocyte lysate assay (BioWhittaker) was 0.001 g. Simul-
taneously, DC were stimulated with 100 ng/ml LPS (Escherichia coli,
strain O26:B6; Sigma-Aldrich), 10 g/ml sPGN, or iPGN. OT-II cells were
purified as described previously (32). Briefly, lymph nodes and spleens
were collected from OT-II mice. After RBC lysis, cells were labeled with
CFSE. Cells were enumerated, and dead cells, stained for trypan blue, were
excluded. After 24 h, DC were washed and 1  104 DC were cocultured
with 1  105 CFSE-labeled OVA TCR transgenic CD4 OT-II T cells in
round-bottom 96-well plates containing 200 l of TCM. Cells were cen-
trifuged, and supernatants were harvested and stored at20°C for cytokine
analysis. Cells were resuspended and incubated with anti-V2-biotin and
V5.1/5.2-PE TCR mAbs (eBioscience) for 30 min at 4°C. Biotinylated
anti-V2 was detected using streptavidin-allophycocyanin (BD Bio-
sciences). Percentages of proliferating OVA-specific CD4 T cells were
determined by gating on cells that were double positive for V2 and
V5.1/5.2. Dead cells and debris were excluded using propidium iodide.
MOG35–55-specific T cell proliferation assay
For evaluation of MOG35–55-specific lymph node cell proliferation, mice
were immunized with MOG35–55 in adjuvant. Mice were sacrificed, and
draining inguinal, brachial, and axillar lymph nodes were isolated at 33
days after immunization. Lymph node cells were cultured for 4 days in
96-well plates in 200 l of RPMI 1640 supplemented with 10% heat-
inactivated FCS (Sigma-Aldrich), 100 U/ml penicillin, and 100 g/ml
streptomycin (BioWhittaker). Cells (4  105/well) were cultured at 37°C









CFA n.a.b 60 8.7  2.9 2.0 20.2 8.8
IFA 0 0 0 0 0
IFA-sPGN 25 60 7.0 2.0 15.8 8.8
250 0 0 0 0
CFAc n.a. 100 9.5 1.6 2.7  0.5 24.0 4.6
IFA-iPGN 25 0 0 0 0
200 0 0 0 0
250 40 12.0 2.0 11.0 4.2
400 60 13.7 1.5 1.7  0.6 9.8  6.7
600 0 0 0 0
a Represented values are from animals that developed EAE.
b n.a., Not applicable.
c Mean values of two separate experiments.
FIGURE 2. Immunization with
PGN-containing adjuvant induces
classical EAE histopathology. Brain
tissues were isolated between 4 and 7
wk after immunization. Frozen brain
sections were stained with hematox-
ylin in combination with MHC-II (A
and B), CD3 (C and D), and B220 (E
and F).
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and 5% CO2 in the presence or absence of 10 g/ml MOG35–55. After 72 h
of culture, 1 Ci of [3H]thymidine (Amersham Biosciences) was added for
16 h. Incorporation of [3H]thymidine was measured in triplicate using a
filtermat harvester and a beta plate counter (PerkinElmer). Supernatants
from MOG35–55 proliferation assays were harvested 96 h after culture,
centrifuged, and stored for further cytokine analysis at 20°C.
Cytokine measurement by ELISA
According to the manufacturer’s instructions, concentrations of IL-4, IL-
10, IL12-p70, IFN-, and TNF- were determined by using OptEIA
ELISA kits (BD Biosciences).
Statistical evaluations
Statistical evaluation was performed using SPSS 11 software. The Mann-
Whitney U test was used to analyze differences in cytokine production and
T cell proliferation. A value of p  0.05 was considered statistically
significant.
Results
Both sPGN and iPGN are potent adjuvants for the induction of
EAE. PGN is a known proinflammatory stimulator of the innate
immune response, but very little is known about the possible role
of PGN in the development of MS and EAE. To determine whether
PGN by itself is a sufficient proinflammatory stimulus for the de-
velopment of EAE, we added highly purified sPGN or iPGN from
S. aureus to an emulsion of IFA and MOG35–55. In three indepen-
dent experiments, standard induction of EAE by immunization of
mice with MOG35–55 in CFA resulted in an EAE incidence of
60–100%, with a normal EAE course (Fig. 1 and Table I). Mice
immunized with MOG35–55 in IFA, as a negative control, did not
develop EAE, as expected. In contrast, addition of sPGN or iPGN
to IFA/MOG35–55 induced EAE with a disease incidence from 40
to 60%. Different dosages of sPGN and iPGN were used for EAE
induction. High dosages of 250 g of sPGN and 600 g of iPGN
did not induce EAE (Table I). Importantly, however, lower PGN
dosages induced EAE with an incidence of 40–60%. The lowest
effective dose for EAE induction with sPGN (25 g/animal) was
10 times lower than with iPGN, in keeping with the higher bio-
logical activity described for sPGN previously. These data dem-
onstrate that PGN is a potent adjuvant and can substitute whole M.
tuberculosis in the induction for EAE.
PGN-adjuvant induces classical EAE histopathology
Brain tissue was examined by histology to assess whether the signs
of paralysis of mice immunized with PGN-containing adjuvant are
associated with a characteristic EAE histopathology. In brain tis-
sue of animals that developed EAE, infiltrates were found con-
taining CD3 T cells, B220 B cells, and MHC-II APC (Fig. 2).
A comparable number of infiltrates and infiltrating cells were de-
tected in EAE mice injected with CFA and IFA-sPGN, whereas the
infiltrate size and number of infiltrating cells in IFA-iPGN-injected
EAE mice was slightly lower (Table II). These data confirm that
paralysis induced with PGN-containing adjuvant is associated with
a characteristic EAE histopathology.
PGN-containing adjuvant promotes MOG35–55-specific Th1 cell
polarization
It has been well established that EAE induction by immunization
with an encephalitogenic Ag in CFA results in the generation of
autoantigen-specific CD4 IFN--producing T cells (34). To ad-
dress whether the PGN component of bacteria is able to generate
MOG35–55-specific Th1 cells, we determined MOG35–55-specific T
cell proliferation and IFN-, IL-4, and IL-10 production at day 33
after immunization. Lymph node cells from mice immunized with
MOG35–55 in CFA proliferated dose dependently and produced
IFN- upon in vitro restimulation with MOG35–55 (Fig. 3). Mice
immunized with MOG35–55 in IFA also showed Ag-specific pro-
liferation, but only low amounts of IFN- were produced. Addition
of sPGN to the immunization mixture resulted in increased Ag-
specific proliferation and IFN- production compared with immu-
nization with IFA/MOG35–55. IL-4 and IL-10 were undetectable in
any of the groups. These data show that PGN creates an inflam-
matory environment. In combination with autoantigen presenta-
tion, PGN can effectively induce autoantigen-specific Th1 cells.
Table II. Histological analysis of infiltrates in EAE brain tissue
Adjuvant PGN (g/animal) Numbera Sizeb





IFA-sPGN 25 10 
25 4–10 
25 10 





a Number, Number of inflammatory foci.
b Infiltrate size, , no infiltrating cells; /, 1–5 cells; , 6–20 cells.
c n.a., Not applicable.
FIGURE 3. Immunization with PGN-containing adjuvant stimulates the
development of MOG35–55-specific Th1 cells. Draining lymph nodes from
five individual mice per group were harvested at day 33 after immuniza-
tion. A, Cells were stimulated in vitro with 10 g/ml MOG35–55, and pro-
liferation was measured after 96 h of culture by [3H]thymidine incorpora-
tion. B, Supernatants were harvested after 96 h of culture and measured by
ELISA for IFN- content. Mean values per group  SD are shown.
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PGN is redistributed from the site of immunization to the
draining lymph nodes
To determine whether PGN is transported from the site of immu-
nization to secondary lymphoid organs during EAE development,
we injected PGN in combination with IFA and MOG35–55 and
isolated draining lymph nodes at different time points after immu-
nization. Two mice per group were injected with either 25 g of
sPGN or 400 g of iPGN in IFA/MOG35–55 emulsions, dosages of
PGN optimal for EAE induction. Two naive mice were used as
negative controls. Axillary, brachial, and inguinal lymph nodes
were isolated and frozen at 4 and 96 h after immunization. Per
mouse, four lymph nodes were analyzed for the presence of PGN-
containing cells. In naive mice, individual PGN-containing cells
were occasionally found in three of eight lymph nodes (38%), in
agreement with previous observations (35, 36). In contrast, we
detected several clusters of PGN-containing cells in 90% of the
draining lymph nodes from mice immunized with sPGN and
iPGN. The number of PGN-containing clusters did not vary be-
tween the time points (data not shown). These data indicate that
APC can take up and transport PGN from the site of immunization
to the draining lymph nodes within hours. Double-labeling exper-
iments identified cells in the PGN-containing clusters as DC ex-
pressing CD11c (Fig. 4). PGN-containing clusters may thus con-
tribute to the development of a proinflammatory environment to
help generate MOG35–55-specific Th1 cells.
Stimulation of DC by PGN increases protein uptake and induces
DC maturation
At the site of immunization, PGN can be recognized by different
cell types, i.e., DC, M, and granulocytes. Because PGN was
mainly observed in DC in the lymph nodes, we assessed whether
PGN stimulates protein uptake, cell maturation, T cell stimulation,
and polarization by this APC subset crucial for priming of T cells.
For these experiments, immature mouse bone marrow-derived DC
were used. To examine the effects of PGN on protein uptake, DC
were incubated with OVA conjugated to FITC in the presence or
absence of 10 g/ml PGN at 4 or 37°C. Different concentrations of
OVA-FITC (0, 0.01, 0.1, and 1 mg/ml) were applied, and uptake
was determined by flow cytometry. Incubation at 4°C showed a
dose-dependent passive uptake of OVA-FITC (data not shown).
Addition of PGN did not alter the uptake of OVA-FITC at 4°C
(Fig. 5A). When cells were cultured at physiological temperature
(37°C), both sPGN and iPGN stimulated the uptake of OVA-FITC
(Fig. 5B).
To assess the effects of PGN on DC maturation, we stimulated
DC with sPGN or iPGN. As a positive control, DC were stimulated
with LPS. Maturation of DC was determined by the expression of
MHC-II, CD40, CD80, and CD86, and by the induction of several
cytokines. Both sPGN and iPGN stimulated expression of MHC-
II, CD40, CD80, and CD80. Stimulation of DC with sPGN effi-
ciently induced expression of MHC-II, CD40, CD80 and CD86 to
a similar or higher level as compared with LPS stimulation. These
molecules were also induced by iPGN, to a similar or lower level
compared with LPS (Fig. 6A). Both sPGN and iPGN induced pro-
duction of several cytokines, but with a different pattern of pro-
duction. Whereas sPGN induced production of all proinflamma-
tory cytokines measured, iPGN induced TNF-, but not IL-6 and
IL-12 (Fig. 6B). IL-10 was not produced under these conditions
(data not shown). As predicted, addition of the LPS antagonist
polymyxin B effectively inhibited LPS-induced maturation marker
expression and cytokine production (Fig. 6B), whereas no inhibi-
tion was seen when cells were stimulated with PGN, demonstrat-
ing that the effects of PGN were not the result of LPS contamina-
tion. Taken together, these data demonstrate that both forms of
PGN can stimulate protein uptake and induce DC maturation in
vitro.
FIGURE 4. PGN is redistributed from the site of immunization to DC in
draining lymph nodes. Draining lymph nodes were isolated at 4 h after s.c.
immunization with MOG35–55 in IFA-sPGN. Frozen sections were stained
by immunofluorescence for DC (CD11c in red, A) and for PGN (green, B).
Overlay in C demonstrates clusters of DC containing PG. D is a light-
microscopic image of the same area.
FIGURE 5. Stimulation of DC by PGN
increases protein uptake. Immature DC were
cultured in the absence or presence of OVA-
FITC. DC were either not stimulated (thin
lines) or stimulated with sPGN (thick lines)
or iPGN (dotted lines). Uptake of OVA-
FITC was determined at 4°C (A) or 37°C (B)
after 30 min of incubation. Histograms rep-
resent the number of CD11c-gated cells.
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PGN-OVA-pulsed DC stimulate T cell proliferation and Th1 cell
polarization
After Ag uptake and migration of DC to the draining lymph nodes,
mature DC will prime naive T cells to proliferate and differentiate
along a certain pathway, depending on the nature of the stimulus.
To address whether sPGN and iPGN are able to stimulate Ag-
specific T cell proliferation and Th1 cell polarization, we used an
in vitro model system. Bone marrow-derived DC were cultured
with OVA in combination with LPS, sPGN, or iPGN. After 24 h,
the DC were incubated with CFSE-labeled naive OVA323–339 TCR
transgenic CD4 T cells. OVA-pulsed DC that were stimulated by
LPS, sPGN, or iPGN, induced an increase in the OVA-specific T
cell proliferation compared with unstimulated cells (Fig. 7, B–E).
Furthermore, both forms of PGN induced significantly increased
levels of IFN- compared with both nonstimulated and LPS-stim-
ulated DC (Fig. 7F). Only low levels of IL-4 and IL-10 were de-
tected in all OVA-pulsed DC-T cell cultures (data not shown). In
summary, these data show that PGN stimulates Ag-specific T cell
proliferation and Th1 cell development.
Discussion
Bacterial and viral components stimulate innate immune re-
sponses that potentially contribute to the development and per-
sistence of autoimmune disease (3, 5). Although it is very dif-
ficult to demonstrate mechanistic links between microbial
agents and MS, it has been shown epidemiologically that ante-
cedent infections are associated with an increased risk of re-
lapse development (4, 5). Components of bacterial agents may
function as physiological adjuvants and stimulate autoantigen-
specific adaptive immune responses. In this study, we show that
PGN, a large bacterial cell wall component, can act as an en-
vironmental factor promoting CNS autoimmune disease devel-
opment via innate immunity.
PGN from a vast array of different bacterial species can be
derived from different anatomical sites, including all mucosa
permanently exposed to the outside world. During bacterial in-
fection, PGN can be released, either from bacterial cells upon
replication or upon uptake and processing by APC. In the ab-
sence of infections, the major bacterial load is located at mu-
cosal sites. At these sites, i.e., the gut, DC may sample bacteria
through the intestinal epithelium and subsequently migrate to
secondary lymphoid organs (37, 38). Even under normal cir-
cumstances, some PGN can be detected in the blood circulation,
within the liver, and within lymphoid tissues, reflecting physi-
ologic processes dealing with exposure to bacterial components
(13, 39 – 45).
FIGURE 6. PGN induces maturation of
bone marrow-derived DC. Immature DC
were either not stimulated (white histogram,
closed line) or stimulated with LPS (white
histograms, dotted line), sPGN, or iPGN
(light-gray and dark-gray histograms, re-
spectively). A, Maturation of DC was deter-
mined by measuring expression of MHC-II,
CD40, CD80, and CD86 by flow cytometry.
Histograms represent the number of CD11c-
gated cells. B, Supernatants were harvested,
and production of IL-6, IL-12p70, and
TNF- was determined by ELISA. Black
bars represent cells that were incubated with
polymyxin B to exclude LPS contamination.
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We therefore hypothesized that bacterial PGN can contribute to
disease development and progression in MS and EAE in the ab-
sence of infection or bacterial replication. To functionally test this
hypothesis, we determined whether EAE could be induced by im-
munization of mice with an encephalitogenic peptide (MOG35–55)
emulsified in IFA supplemented with S. aureus PGN, asking
whether PGN by itself is a sufficient proinflammatory cofactor for
induction of EAE.
For our studies, we used two different types of S. aureus PGN.
We observed functional differences between sPGN and iPGN in
vivo as well as in vitro. Although EAE could be induced with both
types of PGN, the effective dose for EAE induction was 10-fold
lower for sPGN compared with iPGN. In vitro stimulation of DC
with iPGN only induced TNF- production, whereas sPGN could
induce IL-6 and IL-12 in addition to TNF-. These data implicate
that partially degraded PGN is more effective in exerting proin-
flammatory effects than iPGN.
High dosages of both sPGN and iPGN were not able to induce
EAE. The reasons for this are not clear but may be related to
dose-dependent induction of Th1 vs Th2 responses by administra-
tion of TLR ligands in vivo (33). Furthermore, it has been shown
that apoptosis of M is induced by PGN, as described by Fukui et
al. (46). As recently shown, TLR engagement triggers DC apopto-
sis through up-regulation of the proapoptotic Bcl-2 family member
Bim. In this way, both innate and acquired immune system signals
cooperate to determine DC lifespan, and hence also the longevity
of T-DC interaction (47, 48).
L-Lysine or diaminopimelic acid (DAP) at position 3 of the stem
peptide are important structural components of PGN. DAP-type
PGN is present in all Gram-negative bacteria, whereas most Gram-
positive bacteria contain lysine-type PGN (49). The intracellular
PGN-sensing molecules NOD1/2 discriminate between lysine-type
and DAP-type PGN (50). NOD2 is a general sensor for both Gram-
positive and Gram-negative bacteria, through the recognition of
muramyl dipeptide, the minimal motif found in all PGNs (23, 24).
In contrast to NOD2, NOD1 specifically recognizes DAP-type
PGN (21, 22). Bacteria containing L-lysine can induce chronic ar-
thritis, whereas bacteria with other peptides at this position are
nonarthritogenic (51). Several other studies have also identified the
presence of L-lysine as typical for proinflammatory PGN (52–54).
Considering the arthritogenic effects of L-lysine at position 3 of the
stem peptide, one might expect similar findings in EAE develop-
ment. Indeed, we have now shown that EAE can be induced with
lysine-type S. aureus-derived PGN as adjuvant.
Already at 4 h after immunization, PGN-containing clusters
could be detected in the draining lymph nodes. These clusters per-
sisted at least for 7 days after immunization. Others have also
shown the persistence of PG-containing components until at least
63 days after injection of PGN-polysaccharides by muramic acid
detection, a specific component of PGN, through gas chromatog-
raphy and mass spectrometry (40). PGN degradation is mainly
dependent on the enzymes lysozyme and NAMLAA/PGRP-L (55).
Recently, it was found that the PGRP-L is an amidase (28, 29) and
is identical with NAMLAA, which we have characterized in detail
previously (55, 56). In contrast to granulocytes, M and DC lack
NAMLAA/PGRP-L, which may result in incomplete or delayed
PGN degradation and persistence of intracellular PGN. This may
explain why DC in MS brain tissue and in EAE lymph node tissues
contain PGN. The fact that PGN is observed both in lymph nodes
and in the CNS is important, because PGN may act as a physio-
logical proinflammatory adjuvant by stimulating autoantigen-spe-
cific immune responses. Indeed, in the current study, we could
demonstrate that PGN-containing adjuvant enhanced MOG35–55-
specific lymph node cell proliferation and IFN- production at 4
wk after immunization.
DC recognize specific motifs on pathogens by expressing a di-
verse repertoire of pathogen-associated recognition receptors.
Upon bacteria-induced stimulation, DC mature, migrate to the cir-
culation, and prime the adaptive arm of the immune response by
FIGURE 7. PGN stimulates Ag-specific T cell proliferation and Th1 cell polarization. Immature DC were not stimulated (A) or stimulated with OVA
(B) combined with LPS (C), sPGN (D), or iPGN (E) for 24 h. OVA323–339 TCR transgenic CD4 T cells were incubated with all DC populations. A–E,
After 6 days of culture, OVA323–339-specific T cell proliferation was assessed by flow cytometry using CFSE. F, Supernatants were harvested, and
production of IFN- was determined by ELISA. Percentages indicate the number of divided OVA323–339 CD4 T cells. Histograms represent the number
of cell divisions.
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initiating the development of effector T cells in secondary lym-
phoid organs (57). Because we detected PGN within DC in MS
brain, rheumatoid arthritis synovium, and EAE lymphoid tissue,
we addressed the functional role for PGN in EAE development by
in vitro simulation of the different processes involving DC that
occur during immunization for EAE development.
Early events after immunization include uptake of adjuvant and
Ag by DC, inducing their maturation. These processes can be ac-
celerated by whole M. tuberculosis-containing adjuvant as has
been demonstrated in vivo (7). Also bacterial components like
CpG-DNA are able to increase Ag uptake, provided that the Ag is
covalently linked to CpG-DNA (58–60). In concordance with
these studies, we now demonstrate that PGN increases Ag uptake
by DC.
Upon stimulation with TLR ligands or cytokines, DC will ma-
ture and migrate to secondary lymphoid tissues to initiate T cell
activation. It has been demonstrated that S. aureus PGN may serve
as a maturation signal for murine DC, by inducing the expression
of CD86 and MHC-II, and the production of MIP-2 and proin-
flammatory cytokines (61, 62). Also, human monocytes secrete
several chemokines (IL-8, MIP-1) and proinflammatory cyto-
kines (TNF-, IL-1, IL-6, and IL-12) after PGN stimulation, as
shown by cDNA array analysis (63). In agreement with these stud-
ies, we now show that both forms of S. aureus-derived PGN in-
duce DC maturation, as demonstrated by enhanced expression of
MHC-II and costimulatory molecules, and production of proin-
flammatory cytokines. These proinflammatory cytokines, induced
upon TLR stimulation, can exert direct effects on T cell polariza-
tion (i.e., IL-12) (64, 65) and T cell regulation (i.e., IL-6) (66) and
have been implicated in the pathogenesis of MS as well as
EAE (67–69).
Classical EAE induction is dependent on the presence of au-
toantigen and proinflammatory stimuli from adjuvant components
(whole M. tuberculosis). A combination of both factors will result
in the development of autoantigen-specific CD4 Th1 cells within
the secondary lymphoid organs. Not much is known about the
effect of PGN on T cell proliferation and differentiation. A recent
report proposed that Th cell polarization is dependent on differ-
ential TLR ligation (70). Our in vitro studies demonstrate that
OVA-pulsed DC did induce T cell proliferation but did not induce
Th1 cell development. However, when OVA-pulsed DC were co-
incubated with PGN, DC were able to induce OVA-specific Th1
cell development, which confirms previous reports (71). In addi-
tion, PGN-stimulated OVA-DC increased the expansion of OVA-
specific T cells, compared with OVA-pulsed DC alone. These data
provide evidence that PGN stimulates DC-mediated processes and
serves as a potent proinflammatory trigger for the development of
autoantigen-specific Th1 cells.
In this study, we show that the TLR-NOD2 ligand S. aureus
PGN acts as a proinflammatory factor that is involved in the de-
velopment of autoimmune disease of the CNS. The contribution of
PGN on disease development is likely dependent on DC-mediated
processes, because PGN is located within DC in MS brain tissue
and mouse EAE lymph node tissue. We have demonstrated that
PGN is able to potentiate different DC-mediated processes such as
Ag uptake, DC maturation, and subsequent induction and stimu-
lation of autoantigen-specific Th1 cell development. Targeting
PGN receptors or their respective signaling pathways may well
become a novel therapeutic strategy for the treatment of autoim-
mune disease in humans.
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